Examkin

Question

Difficulty: MediumPharmacologic Interventions

A 6262-year-old man is evaluated on the cardiology floor prior to hospital discharge. Two days ago, he was admitted for a non-ST-segment elevation myocardial infarction (NSTEMI). He subsequently underwent coronary angiography and percutaneous coronary intervention with the placement of a drug-eluting stent in the right coronary artery. His past medical history includes hypertension, type 22 diabetes mellitus, and osteoarthritis. His home medications, which included lisinopril, metformin, and ibuprofen, were temporarily held on admission. Echocardiography performed yesterday shows a left ventricular ejection fraction of 45%45\%. Vital signs are temperature 37.0∘C37.0^\circ C (98.6∘F98.6^\circ F), blood pressure 126/78126/78 mmHg, and pulse 6868/min. Laboratory studies show a serum creatinine of 1.11.1 mg/dL. Which of the following pharmacologic interventions are appropriate for this patient at discharge? (Select all that apply)

  1. Prescribe dual antiplatelet therapy with aspirin and a P2Y12 inhibitorAnswer
  2. Initiate a high-intensity statin such as atorvastatinAnswer
  3. Initiate a cardioselective beta-blocker such as metoprololAnswer
  4. D
    Resume the patient's home ibuprofen for osteoarthritis
  5. E
    Prescribe oral apixaban to prevent coronary stent thrombosis

Answer

The appropriate pharmacologic interventions for this patient at discharge include prescribing dual antiplatelet therapy (aspirin and a P2Y12 inhibitor), initiating a high-intensity statin, and initiating a cardioselective beta-blocker.
Post-myocardial infarction secondary prevention following percutaneous coronary intervention (PCI) requires several key pharmacologic interventions to reduce mortality and prevent recurrence. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (such as clopidogrel, ticagrelor, or prasugrel) is essential to prevent early and late stent thrombosis. A high-intensity statin (e.g., atorvastatin 4040-8080 mg or rosuvastatin 2020-4040 mg) is indicated to stabilize endothelial plaques and reduce future cardiovascular events, regardless of the patient's baseline lipid panel. Additionally, a cardioselective beta-blocker (e.g., metoprolol succinate) should be initiated to reduce myocardial oxygen demand, limit adverse ventricular remodeling, and decrease the risk of malignant ventricular arrhythmias, particularly in patients with a reduced or borderline ejection fraction (LVEF 45%45\%). Though not an option choice, resuming his ACE inhibitor (lisinopril) is also indicated due to his diabetes, hypertension, and reduced ejection fraction.

Step-by-Step Solution

1
Identify the patient's clinical scenario.
The patient is being discharged after an NSTEMI treated with a drug-eluting stent (DES). He also has hypertension, diabetes, and an ejection fraction of 45%.
Accurate identification of the patient's diagnoses and recent procedures is essential to formulate a guideline-directed medical therapy (GDMT) regimen.
2
Determine the standard-of-care secondary prevention medications required post-myocardial infarction.
The core regimen includes dual antiplatelet therapy (DAPT), a high-intensity statin, a beta-blocker, and an ACE inhibitor or ARB.
These medication classes have a proven mortality and morbidity benefit in patients recovering from acute coronary syndrome.
3
Evaluate the safety and indications of other proposed medications (ibuprofen, apixaban).
Ibuprofen is contraindicated post-MI, and apixaban is not indicated for stent thrombosis prevention.
Avoiding contraindicated medications (like NSAIDs) and unnecessary high-risk medications (like DOACs without a clear indication) is crucial for patient safety.

Key Concept

Guideline-directed medical therapy for secondary prevention following a myocardial infarction and percutaneous coronary intervention.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic